Business Context and Reporting Period
This Form 8-K Current Report was filed by MediciNova, Inc. on June 16, 2010, covering events occurring on June 10, 2010, and June 14, 2010. The filing primarily addresses the appointment of a new executive officer and the results of the Company's Annual Meeting of Stockholders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and executive compensation rather than financial performance metrics.
Material Changes and Executive Appointments
Appointment of Chief Business Officer
On June 14, 2010, MediciNova entered into an Executive Employment Agreement with Michael Coffee, effective immediately as Chief Business Officer. Mr. Coffee had previously served as a consultant since March 2010 and was formerly the Chief Business Officer of Avigen, Inc., which MediciNova acquired in December 2009.
Compensation Structure
- Base Salary: $300,000 per year, subject to annual adjustment.
- Termination Notice: Three months' written notice required by either party, or severance pay equal to one-half of the annual base salary in lieu of notice.
- Change of Control Severance: If terminated without cause or resigns for good reason within 12 months of a change of control, Mr. Coffee receives accrued salary, pro rata bonus, and a lump sum equal to two times his base salary plus any bonus amount.
- Post-Termination Benefits: 24 months of health benefits and up to 12 months of outplacement counseling under change of control scenarios.
- Consulting Option: Upon termination for any reason, the Company may engage Mr. Coffee as a consultant at a rate of 15% of his annual base salary per quarter.
Corporate Governance and Stockholder Votes
The Company held its Annual Meeting of Stockholders on June 10, 2010. Key outcomes included:
- Director Elections: Arlene Morris and John K.A. Prendergast, Ph.D., were elected as Class III directors until 2013.
- Arlene Morris: 6,401,482 votes for; 52,801 withheld.
- John K.A. Prendergast: 6,393,219 votes for; 61,064 withheld.
- Auditor Ratification: Stockholders ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2010.
- Votes: 7,080,270 for; 40,401 against; 19,900 abstained.
Investor Verification Checklist
- Verify the total equity compensation granted to Michael Coffee under the Company's equity incentive plans, as the filing mentions accelerated vesting but does not specify grant amounts.
- Review the full text of the Executive Employment Agreement (Exhibit 10.1) for specific definitions of "good reason" and "change of control."
- Confirm the Company's current cash position to assess the ability to fund potential severance obligations (up to 2x base salary) in the event of a change of control.
- Monitor the integration of Mr. Coffee's prior experience with Avigen, Inc. into MediciNova's business strategy.